To the Editor:

Human parvovirus B19 is a small single-stranded DNA virus of the family Parvoviridae. B19 is the only parvovirus known to cause clinical illness in humans beings. It was discovered unexpectedly in serum from blood-bank donors and since then has been associated with several human illnesses. Generally, B19 causes a self-limited illness with improvement in a few weeks without sequelae. However, in several groups, the infection can produce life-threatening complications and even death. In patients with chronic increased red blood
cell (RBC) production, it may induce aplastic crisis in which erythroid production is acutely reduced. In patients with congenital or acquired immunodeficiency who are unable to produce neutralizing antibodies, the infection can cause chronic bone marrow (BM) failure, usually manifested as anemia, because the erythroid progenitors have greater affinity. It has been described in congenital combined immunodeficiency with decreased Ig (Nezelof syndrome), in children with acute lymphocytic leukemia in chemotherapy, in patients with acquired immunodeficiency syndrome, and after BM transplantation (BMT). However, it has occasionally been suspected to be a cause of graft failure after bone marrow or peripheral blood stem cell (PBSC) transplantation. We report a case of graft failure after PBSC transplantation whose laboratory findings showed parvovirus infection and its resolution coincident with intravenous Ig (IVIg) treatment.

A 58-year-old woman was diagnosed as having breast cancer stage III-B. Because of the high risk of relapse, six cycles of adjuvant chemotherapy was included in a program of high-dose chemotherapy supported with hematopoietic stem cells mobilized with granulocyte colony-stimulating factor (10 μg/kg/d for 5 days). A total of 2.5 × 10^6 CD34+ cells/kg and 9.2 × 10^6 mononuclear cells/kg was collected. She was conditioned with cyclophosphamide, carboplatin, and ticlopidine at doses described elsewhere. On the day of infusion, she presented fever without clinical localization. Empirical antibiotic therapy with cefazidime and amikacin was initiated, but low-grade fever persisted in the following days; vancomycin was added because Staphylococcus coagulase-negative were isolated in blood cultures. The neutrophil count was 0.2 × 10^9/L on day +9, decreasing thereafter to less than 0.1 × 10^9/L and persisting at that level until day +41, when a therapeutic trial with IVIg was initiated. The absence of reticulocyte and platelet increase coincide with high transfusion requirements (10 RBC units and 11 occasions of platelet transfusion during the first 40 days of transplantation). The BM study performed on days +14 and +30 showed most cellularity to be low, although problems are possible.

Healthy people, B19 infection is a benign and self-limited illness and treatment is not required. However, in patients with chronic hemolytic anemia and congenital or acquired immunodeficiency, treatment is mandatory. There are reports in which IVIg has been used with resolution of viremia and improvement in RBC indices due to the neutralizing activity of a commercial Ig preparation against erythropoietic suppression by human parvovirus. The optimal dose is unclear. Most reports use high doses (>2 g/kg), but, in others, resolution has been described with lesser doses (<1 g/kg). The clinical evolution of this patient suggests that parvovirus infection should be considered a treatable cause of primary graft failure.

REFERENCES
Engraftment failure associated with peripheral blood stem cell transplantation after B19 parvovirus infection [letter]

C Solano, O Juan, C Gimeno and J Garcia-Conde